{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:53:01Z","timestamp":1793404381250,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020275","name":"TauRx Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tjpad.2026.100480","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:55:37Z","timestamp":1769036137000},"page":"100480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Claude M","family":"Wischik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stefanacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bentham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-3021","authenticated-orcid":false,"given":"Gordon K","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-0813","authenticated-orcid":false,"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emer","family":"MacSweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Tai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tay Siew","family":"Choon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahe","family":"Asvatourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Muehlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Priel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenecia","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Downie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Pringle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M. D","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-4314","authenticated-orcid":false,"given":"Tom","family":"Baddeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-3920","authenticated-orcid":false,"given":"Charles R","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-4476","authenticated-orcid":false,"given":"Lewis K","family":"Penny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-4949","authenticated-orcid":false,"given":"Mohammad","family":"Arastoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0620-8673","authenticated-orcid":false,"given":"Roger","family":"Staff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5555-4129","authenticated-orcid":false,"given":"Anca-Larisa","family":"Sandu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Shiells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3378-7028","authenticated-orcid":false,"given":"Serena","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9396-0443","authenticated-orcid":false,"given":"Nafeesa","family":"Nazlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9570-9416","authenticated-orcid":false,"given":"Emily","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-6279","authenticated-orcid":false,"given":"Claire","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern O","family":"Schelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100480_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2026.100480_bib0002","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.3390\/jcm13113098","article-title":"Novel therapeutic strategies in Alzheimer\u2019s Disease: pitfalls and challenges of anti-amyloid therapies and beyond","volume":"13","author":"Tondo","year":"2024","journal-title":"J Clin MedBib_Entry"},{"key":"10.1016\/j.tjpad.2026.100480_bib0003","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0004","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14283\/jpad.2022.63","article-title":"Oral tau aggregation inhibitor for Alzheimer\u2019s disease: design, progress and basis for selection of the 16 mg\/day dose in a phase 3, randomized, placebo-controlled trial of hydromethylthionine mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100480_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9440(10)64573-7","article-title":"Staging of cytoskeletal and \u03b2-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer\u2019s disease","volume":"157","author":"Mukaetova-Ladinska","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0006","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2026.100480_bib0007","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.tjpad.2026.100480_bib0008","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","article-title":"Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease","volume":"290","author":"Harrington","year":"2015","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.tjpad.2026.100480_bib0009","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.jmb.2018.08.010","article-title":"Cysteine-independent inhibition of Alzheimer\u2019s disease-like paired helical filament assembly by leuco-methylthioninium (LMT)","volume":"430","author":"Al-Hilaly","year":"2018","journal-title":"J Mol Biol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0010","doi-asserted-by":"crossref","unstructured":"Wischik C.M., Edwards P.C., Lai R.Y.K., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proceedings of the National Academy of Sciences, USA 1996;93:11213\u20138. https:\/\/doi.org\/10.1073\/pnas.93.20.11213.","DOI":"10.1073\/pnas.93.20.11213"},{"key":"10.1016\/j.tjpad.2026.100480_bib0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jnc.15553","article-title":"Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine","volume":"160","author":"Kondak","year":"2022","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2026.100480_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310810","article-title":"Mitochondrial effects of hydromethylthionine, rivastigmine and memantine in tau-transgenic mice","volume":"24","author":"Kondak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjpad.2026.100480_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00213-008-1394-2","article-title":"Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine","volume":"202","author":"Deiana","year":"2009","journal-title":"Psychopharmacol (Berl)"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100480_bib0014","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FBP.0000000000000865","article-title":"Effects of HMTM and rivastigmine in a symptomatic mouse model of Alzheimer\u2019s disease","volume":"37","author":"Robinson","year":"2026","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3233\/JAD-190772","article-title":"Concentration-dependent activity of hydromethylthionine on cognitive decline and brain atrophy in mild to moderate Alzheimer\u2019s disease","volume":"72","author":"Schelter","year":"2019","journal-title":"J Alzheimer 19s Dis"},{"key":"10.1016\/j.tjpad.2026.100480_bib0016","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2026.100480_bib0017","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J Alzheimer 19s Dis"},{"key":"10.1016\/j.tjpad.2026.100480_bib0019","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-191173","article-title":"Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia","volume":"75","author":"Shiells","year":"2020","journal-title":"J Alzheimer 19s Dis"},{"key":"10.1016\/j.tjpad.2026.100480_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimer 19s Dis"},{"key":"10.1016\/j.tjpad.2026.100480_bib0021","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer 19s Dement"},{"key":"10.1016\/j.tjpad.2026.100480_bib0022","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer 19s Dement"},{"key":"10.1016\/j.tjpad.2026.100480_bib0023","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer 19s Dement"},{"key":"10.1016\/j.tjpad.2026.100480_bib0024","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2026.100480_bib0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer Disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0026","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2026.100480_bib0027","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1109\/42.640753","article-title":"The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI","volume":"16","author":"Freeborough","year":"1997","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.tjpad.2026.100480_bib0030","unstructured":"van Maanen E., Gon\u00e7alves A., Chen L., Floris Fauchet F., Cristea S., Smith J., et al. Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer\u2019s disease explains unexpected phase 3 trial results 2025 (Submitted, under review)."},{"key":"10.1016\/j.tjpad.2026.100480_bib0031","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0036","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/brain\/awaa342","article-title":"Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer\u2019s disease","volume":"143","author":"Benedet","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.tjpad.2026.100480_bib0032","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Alzheimer disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0033","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2026.100480_bib0034","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0035","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","article-title":"Associations of longitudinal plasma p-tau181 and NfL with tau-PET, a\u03b2-PET and cognition","volume":"92","author":"Rauchmann","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.tjpad.2026.100480_bib0037","article-title":"Neurofilament light (NfL) chain levels predict clinical decline in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"9","author":"Thomas","year":"2025","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.tjpad.2026.100480_bib0038","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0039","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","article-title":"Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment","volume":"15","author":"Mundada","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100480_bib0040","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.tjpad.2026.100480_bib0041","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.tjpad.2026.100480_bib0043","series-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","article-title":"Choice of control group and related issues in clinical trials E10","year":"2000"},{"key":"10.1016\/j.tjpad.2026.100480_bib0044","unstructured":"MHRA. MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions 2025. https:\/\/www.gov.uk\/government\/publications\/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions\/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions (accessed August 30, 2025)."},{"key":"10.1016\/j.tjpad.2026.100480_bib0046","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00401-010-0789-4","article-title":"The pathological process underlying Alzheimer\u2019s disease in individuals under thirty","volume":"121","author":"Braak","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2026.100480_bib0047","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","article-title":"Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease","volume":"26","author":"Dujardin","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2026.100480_bib0045","article-title":"Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer\u2019s disease with hydromethylthionine mesylate using external control data","author":"Schelter","year":"2025","journal-title":"J Prev Alzheimer 19s Dis"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072600004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072600004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:39:48Z","timestamp":1773261588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072600004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S227458072600004X"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100480","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100480"}}